Skip to main content

Table 1 Select ongoing clinical trials of DLL3-targeted agents in SCLC

From: DLL3: an emerging target in small cell lung cancer

Treatment Setting Primary outcome Phase N ID
Rovalpituzumab tesirine, cisplatin, etoposide First line Safety and PFS 1 28 NCT02819999
Rovalpituzumab tesirine, nivolumab, ipilimumab Second line Safety 1/2 42 NCT03026166
Rovalpituzumab tesirine versus topotecan Second line OS 3 444 NCT03061812
Rovalpituzumab tesirine, dexamethasone Maintenance PFS, OS 3 740 NCT03033511
AMG 757 Second line Safety, tolerability, and PK 1 92 NCT03319940
AMG 119 Second line Safety and tolerability 1 41 NCT03392064
  1. MTD maximum tolerated dose, OS overall survival, PFS progression-free survival, PK pharmacokinetics, RP2D recommended phase 2 dose, SCLC small cell lung cancer. Detailed information relevant to these clinical trials can be found at